Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.

Denali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an ...

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

Pitcairn Co. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 3rd quarter, ...

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the ...

DNLI has been the topic of a number of recent research reports. Bank of America lifted their target price on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a ...

Denali Therapeutics (NASDAQ: NASDAQ:DNLI) is changing the neurodegenerative disease landscape - one traditionally characterized by failed trials and a grim outlook. While almost all investors ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided ...

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.